EWA
NRIX icon

EverSource Wealth Advisors’s Nurix Therapeutics NRIX Stock Holding History

EverSource Wealth Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08K Buy
168
+158
+1,580% +$2.69K ﹤0.01% 3385
2026
Q1 		$155 Buy
+10
New +$166 ﹤0.01% 4228
2025
Q3 		– Sell
-129
Closed -$1.47K – 4428
2025
Q2 		$1.47K Buy
+129
New +$1.39K ﹤0.01% 3609
2025
Q1 		– Sell
-33
Closed -$622 – 4126
2024
Q4 		$622 Buy
+33
New +$756 ﹤0.01% 3116

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's NRIX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Nurix Therapeutics (NRIX) stake by 1,580% in Q2 2026, buying an estimated $2.69K and bringing the position to 168 shares worth $4.08K. The position accounts for ﹤0.01% of the portfolio, ranked #3385.

EverSource Wealth Advisors first reported a position in NRIX in Q4 2024 and has held it in 4 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • EverSource Wealth Advisors held 168 shares of Nurix Therapeutics worth $4.08K as of Q2 2026.
  • EverSource Wealth Advisors bought 158 Nurix Therapeutics shares in Q2 2026, an estimated $2.69K.
  • Nurix Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3385 holding.
  • EverSource Wealth Advisors first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.